Europe Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity

October 2020 | 116 pages | ID: E123D9A794DAEN
GMD Research

Abstracts

Europe pharmaceutical contract manufacturing market accounted for $24.4 billion in 2019 and will grow by 6.0% annually over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity.

Highlighted with 38 tables and 53 figures, this 116-page report “Europe Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country.

Based on Category, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Pharmaceutical Industry
• Biopharmaceutical Industry

Based on Product, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Active Pharmaceutical Ingredients (API)

• Branded API Manufacturing
• Generic API Manufacturing

Finished Dosage Formulations (FDF)

• Solid Dosage
• Oral Liquids
• Parenteral/Injectables
• Other FDFs

Secondary Packaging

Based on Phase, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Clinical Manufacturing
• Commercial Manufacturing

Based on Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Sterile Products
• Non-Sterile Products

Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications

Geographically, the following national/local markets are fully investigated:

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Europe pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF EUROPE MARKET BY CATEGORY

3.1 Market Overview by Category
3.2 Pharmaceutical Industry
3.3 Biopharmaceutical Industry

4 SEGMENTATION OF EUROPE MARKET BY PRODUCT

4.1 Market Overview by Product
4.2 Active Pharmaceutical Ingredients (API)
  4.2.1 Branded API Manufacturing
  4.2.2 Generic API Manufacturing
4.3 Finished Dosage Formulations (FDF)
  4.3.1 Solid Dosage
  4.3.2 Oral Liquids
  4.3.3 Parenteral/Injectables
  4.3.4 Other FDFs
4.4 Secondary Packaging

5 SEGMENTATION OF EUROPE MARKET BY PHASE

5.1 Market Overview by Phase
5.2 Clinical Manufacturing
5.3 Commercial Manufacturing

6 SEGMENTATION OF EUROPE MARKET BY TYPE

6.1 Market Overview by Type
6.2 Sterile Products
6.3 Non-Sterile Products

7 SEGMENTATION OF EUROPE MARKET BY THERAPEUTIC APPLICATION

7.1 Market Overview by Therapeutic Application
7.2 Infectious Diseases
7.3 Oncology
7.4 Metabolic Disorders
7.5 Cardiovascular Disorders
7.6 Central Nervous System
7.7 Pulmonary Disorders
7.8 Gastrointestinal Disorders
7.9 Other Therapeutic Applications

8 EUROPEAN MARKET 2019-2030 BY COUNTRY

8.1 Overview of European Market
8.2 Germany
8.3 UK
8.4 France
8.5 Spain
8.6 Italy
8.7 Russia
8.8 Rest of European Market

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH

10 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT

10.1 Risk Evaluation of Europe Market
10.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Europe Pharmaceutical Contract Manufacturing Market, 2019-2030
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. Main Product Trends and Market Opportunities in Europe Pharmaceutical Contract Manufacturing Market
Table 4. Europe Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, $ bn
Table 5. Europe Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 6. Europe Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn
Table 7. Europe Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn
Table 8. Europe Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 9. Europe Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, $ bn
Table 10. Europe Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 11. Europe Pharmaceutical Contract Manufacturing Market by Country, 2019-2030, $ bn
Table 12. Germany Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 13. Germany Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 14. Germany Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 15. UK Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 16. UK Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 17. UK Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 18. France Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 19. France Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 20. France Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 21. Spain Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 22. Spain Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 23. Spain Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 24. Italy Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 25. Italy Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 26. Italy Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 27. Russia Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 28. Russia Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 29. Russia Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 30. Pharmaceutical Contract Manufacturing Market in Rest of Europe by Country, 2019-2030, $ bn
Table 31. Breakdown of Europe Market by Key Vendor, 2019, %
Table 32. Aenova Group: Company Snapshot
Table 33. Aenova Group: Business Segmentation
Table 34. Aenova Group: Product Portfolio
Table 35. Aenova Group: Revenue, 2016-2018, $ bn
Table 36. Aenova Group: Recent Developments
Table 37. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 38. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Pharmaceutical Contract Manufacturing Market
Figure 8. Primary Restraints and Impact Factors of Europe Pharmaceutical Contract Manufacturing Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of Europe Pharmaceutical Contract Manufacturing Market
Figure 11. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue
Figure 12. Europe Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)
Figure 13. Europe Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn
Figure 14. Europe Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn
Figure 15. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue
Figure 16. Europe Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%)
Figure 17. Europe Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn
Figure 18. Europe Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn
Figure 19. Europe Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn
Figure 20. Europe Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn
Figure 21. Europe Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn
Figure 22. Europe Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn
Figure 23. Europe Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn
Figure 24. Europe Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn
Figure 25. Europe Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn
Figure 26. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue
Figure 27. Europe Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%)
Figure 28. Europe Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn
Figure 29. Europe Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn
Figure 30. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue
Figure 31. Europe Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%)
Figure 32. Europe Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn
Figure 33. Europe Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn
Figure 34. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue
Figure 35. Europe Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)
Figure 36. Europe Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn
Figure 37. Europe Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn
Figure 38. Europe Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn
Figure 39. Europe Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn
Figure 40. Europe Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn
Figure 41. Europe Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn
Figure 42. Europe Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn
Figure 43. Europe Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn
Figure 44. Breakdown of European Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue
Figure 45. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 46. Pharmaceutical Contract Manufacturing Market in Germany, 2019-2030, $ bn
Figure 47. Pharmaceutical Contract Manufacturing Market in UK, 2019-2030, $ bn
Figure 48. Pharmaceutical Contract Manufacturing Market in France, 2019-2030, $ bn
Figure 49. Pharmaceutical Contract Manufacturing Market in Spain, 2019-2030, $ bn
Figure 50. Pharmaceutical Contract Manufacturing Market in Italy, 2019-2030, $ bn
Figure 51. Pharmaceutical Contract Manufacturing Market in Russia, 2019-2030, $ bn
Figure 52. Pharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030, $ bn
Figure 53. Growth Stage of Europe Pharmaceutical Contract Manufacturing Industry over the Forecast Period